Short interfering RNA (siRNA) analogues

US8653252B2 · kind B2 · utility

Assignee

• Santaris Pharma A/S · DK

Inventors

• Joachim Elmén · Stockholm, SE
• Claes Wahlestedt · Palm Beach, US
• Zicai Liang · Beijing, CN
• Anders Malling Sørensen · Älvsbyn, SE
• Henrik Ørum · Neubiberg, DE
• Troels Koch · Copenhagen, DK

Key dates

• Filing date: Mar 22, 2004
• Grant date: Feb 18, 2014
• Expiry date: Dec 31, 2027

Classification

• Technology area (CPC Y): Emerging Cross-Sectional Technologies
• CPC primary: Y02A50/30
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention is directed to novel double-stranded short interfering (siRNA) analogues comprising locked nucleic acid (LNA) monomers. Such compounds induces sequence-specific post-transcriptional gene silencing in many organisms by a process known as RNA interference (RNAi). The compounds disclosed herein has improved properties compared to non-modified siRNAs and may, accordingly, be useful as therapeutic agents, e.g., in the treatment of various cancer forms. More particularly, the present invention is directed to siRNA analogues comprising a sense strand and an antisense strand, wherein each strand comprises 12-35 nucleotides and wherein the siRNA analogues comprise at least one locked nucleic acid (LNA) monomer.